GRAL vs LUCD
GRAL: GRAIL is developing Galleri, a blood-based multi-cancer early detection test designed to detect many types of cancer from a single draw and pinpoint the tissue of origin, pending FDA approval. LUCD: Lucid Diagnostics develops EsoGuard, the first noninvasive DNA test for early detection of esophageal cancer precursors in millions of chronic GERD patients at risk.
Side-by-side fundamentals
| Metric | GRAL | LUCD | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $69.48 | $0.9671 | |
| Market cap as of 2026-08-09 | $3.1B | $196M | |
| Net margin as of 2026-08-09 | -253.2% | -876.7% | GRAL higher |
| Gross margin as of 2026-08-09 | +49.3% | -31.4% | GRAL higher |
| Operating margin as of 2026-08-09 | -348.7% | -980.6% | GRAL higher |
| ROE as of 2026-08-09 | -16.4% | -370.2% | GRAL higher |
| ROA as of 2026-08-09 | -14.3% | -108.2% | GRAL higher |
| Debt / equity as of 2026-08-09 | 0.00 | 6.30 | GRAL lower |
| Revenue growth (YoY) as of 2026-08-09 | +19.4% | +23.0% | LUCD higher |
| Revenue CAGR (3y) SEC XBRL | +25.7% | +105.6% | LUCD higher |
| Beta as of 2026-08-09 | 1.91 | 1.17 | |
| 1-year return as of 2026-08-07 close | +110.8% | -1.4% | GRAL higher |
Fundamentals: market data, as of 2026-08-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.